Benita Katzenellenbogen

Benita Katzenellenbogen's AcademicInfluence.com Rankings

Biology

#4207

World Rank

#6306

Historical Rank

#1613

USA Rank

Cell Biology

#105

World Rank

#110

Historical Rank

#40

USA Rank

Physiology

#82

World Rank

#203

Historical Rank

#20

USA Rank

biology Degrees

Download Badge

Biology

Why Is Benita Katzenellenbogen Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Benita S. Katzenellenbogen née Schulman is an American physiologist and cell biologist at the University of Illinois at Urbana-Champaign. She has studied cancer, endocrinology, and women's health, focusing on nuclear receptors. She also dedicated efforts to focusing on improving the effectiveness of endocrine therapies in breast cancer.

(See a Problem?)

Benita Katzenellenbogen's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. (1986) (1287)
Nongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors Dissociation from Transcriptional Activity (2001) (1210)
Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. (2003) (823)
Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. (2000) (740)
Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. (1994) (694)
Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. (2001) (683)
Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. (1996) (535)
Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. (1993) (462)
Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. (1994) (462)
Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. (1987) (452)
Selective Estrogen Receptor Modulators (2004) (440)
Whole-Genome Cartography of Estrogen Receptor α Binding Sites (2007) (435)
Activation of Estrogen Receptor-α by the Heavy Metal Cadmium (2000) (403)
Estrogen receptors: bioactivities and interactions with cell signaling pathways. (1996) (402)
Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta. (2004) (400)
The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. (1999) (400)
Localization of androgen and estrogen receptors in adult male mouse reproductive tract. (2002) (386)
Estrogen receptor activation function 1 works by binding p160 coactivator proteins. (1998) (376)
Direct Acetylation of the Estrogen Receptor α Hinge Region by p300 Regulates Transactivation and Hormone Sensitivity* (2001) (358)
Dynamics of steroid hormone receptor action. (1980) (346)
Characterization of the Biological Roles of the Estrogen Receptors, ERα and ERβ, in Estrogen Target Tissues in Vivo through the Use of an ERα-Selective Ligand (2002) (343)
Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism (2002) (341)
Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression (2003) (319)
An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. (1999) (306)
Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. (1984) (292)
Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology (2000) (291)
Impact of Estrogen Receptor β on Gene Networks Regulated by Estrogen Receptor α in Breast Cancer Cells (2006) (287)
Regulation of estrogen receptor messenger ribonucleic acid and protein levels in human breast cancer cell lines by sex steroid hormones, their antagonists, and growth factors. (1989) (269)
Estrogen Imprinting of the Developing Prostate Gland Is Mediated through Stromal Estrogen Receptor α Studies with αERKO and βERKO Mice (2001) (268)
Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. (1996) (268)
Transcription activation by the human estrogen receptor subtype beta (ER beta) studied with ER beta and ER alpha receptor chimeras. (1998) (258)
The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. (1995) (256)
Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. (1996) (247)
A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. (2000) (243)
Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. (2006) (240)
Response-Specific and Ligand Dose-Dependent Modulation of Estrogen Receptor (ER) α Activity by ERβ in the Uterus (2003) (235)
Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: distinct and common target genes for these receptors. (2004) (235)
Membrane and Nuclear Estrogen Receptor Alpha Actions: From Tissue Specificity to Medical Implications. (2017) (234)
Novel Ligands that Function as Selective Estrogens or Antiestrogens for Estrogen Receptor-α or Estrogen Receptor-β. (1999) (231)
Ligand-dependent, transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor. (1995) (227)
Different Regions in Activation Function-1 of the Human Estrogen Receptor Required for Antiestrogen- and Estradiol-dependent Transcription Activation* (1996) (223)
Effects of estrogens and antiestrogens on estrogen receptor dynamics and the induction of progesterone receptor in MCF-7 human breast cancer cells. (1982) (222)
Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. (2010) (220)
Activation of estrogen receptor-alpha by the heavy metal cadmium. (2000) (213)
Ligand-modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines. (1988) (213)
Antagonists Selective for Estrogen Receptor α. (2002) (212)
Conformational Changes and Coactivator Recruitment by Novel Ligands for Estrogen Receptor-α and Estrogen Receptor-β: Correlations with Biological Character and Distinct Differences among SRC Coactivator Family Members. (2000) (206)
Synergistic activation of estrogen receptor-mediated transcription by estradiol and protein kinase activators. (1993) (206)
Progesterone receptor regulation in uterine cells: stimulation by estrogen, cyclic adenosine 3',5'-monophosphate, and insulin-like growth factor I and suppression by antiestrogens and protein kinase inhibitors. (1991) (204)
Estrogen receptors: selective ligands, partners, and distinctive pharmacology. (2000) (202)
Estrogen action and male fertility: Roles of the sodium/hydrogen exchanger-3 and fluid reabsorption in reproductive tract function (2001) (199)
Genome-Wide Analysis of Estrogen Receptor α DNA Binding and Tethering Mechanisms Identifies Runx1 as a Novel Tethering Factor in Receptor-Mediated Transcriptional Activation (2010) (199)
Estrogen and antiestrogen action in reproductive tissues and tumors. (1979) (198)
Zearalenones: characterization of the estrogenic potencies and receptor interactions of a series of fungal beta-resorcylic acid lactones. (1979) (196)
Estrogen action in vitro. Induction of the synthesis of a specific uterine protein. (1972) (195)
Synthesis and biological evaluation of a novel series of furans: Ligands selective for estrogen receptor α (2001) (193)
Regulation of progesterone receptor messenger ribonucleic acid and protein levels in MCF-7 cells by estradiol: analysis of estrogen's effect on progesterone receptor synthesis and degradation. (1988) (192)
Inhibitory cross-talk between steroid hormone receptors: differential targeting of estrogen receptor in the repression of its transcriptional activity by agonist- and antagonist-occupied progestin receptors (1995) (192)
Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors. (2008) (191)
Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation (2016) (191)
Identification of multiple, widely spaced estrogen-responsive regions in the rat progesterone receptor gene. (1994) (190)
Cloning of the rat progesterone receptor gene 5'-region and identification of two functionally distinct promoters. (1993) (189)
Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen. (1990) (188)
Antiestrogen-binding sites distinct from the estrogen receptor: subecellular localization, ligand specificity, and distribution in tissues of the rat. (1983) (188)
Regulation of progesterone receptor gene expression and growth in the rat uterus: modulation of estrogen actions by progesterone and sex steroid hormone antagonists. (1993) (188)
Estrogenic activity of the insecticide chlordecone (Kepone) and interaction with uterine estrogen receptors. (1979) (187)
Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. (1997) (187)
Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. (1989) (185)
Structure-function analysis of the hormone binding domain of the human estrogen receptor by region-specific mutagenesis and phenotypic screening in yeast. (1993) (181)
Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. (2006) (180)
Antiestrogen action in the uterus: biological ineffectiveness of nuclear bound estradiol after antiestrogen. (1975) (178)
Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc. (2004) (177)
Tamoxifen down-regulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance (2011) (176)
Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. (2006) (173)
Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. (2006) (170)
Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. (1982) (170)
Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. (1990) (167)
The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens. (1997) (167)
Indazole estrogens: highly selective ligands for the estrogen receptor beta. (2005) (164)
Estrogen receptor transcription and transactivation Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer (2000) (164)
Estrogen Receptors alpha and beta as determinants of gene expression: influence of ligand, dose, and chromatin binding. (2008) (163)
Therapeutic targeting in the estrogen receptor hormonal pathway. (2004) (159)
Pyrazolo[1,5-a]pyrimidines: estrogen receptor ligands possessing estrogen receptor beta antagonist activity. (2004) (156)
Defining the "S" in SERMs (2002) (156)
Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer. (2008) (150)
Nuclear hormone receptors: ligand-activated regulators of transcription and diverse cell responses. (1996) (149)
Analysis of Estrogen Receptor Interaction with a Repressor of Estrogen Receptor Activity (REA) and the Regulation of Estrogen Receptor Transcriptional Activity by REA* (2000) (148)
Editorial: A New Actor in the Estrogen Receptor Drama-Enter ER-β. (1997) (145)
Caveolin-1 Potentiates Estrogen Receptor α (ERα) Signaling (1999) (143)
Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by a density shift technique. (1984) (137)
Examination of the DNA-binding ability of estrogen receptor in whole cells: implications for hormone-independent transactivation and the actions of antiestrogens (1992) (136)
NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses. (2008) (135)
Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: studies with alphaERKO and betaERKO mice. (2001) (135)
Transcriptional Regulation of the Human Quinone Reductase Gene by Antiestrogen-liganded Estrogen Receptor-α and Estrogen Receptor-β* (1998) (134)
Temporal relationships between hormone receptor binding and biological responses in the uterus: studies with short- and long-acting derivatives of estriol. (1976) (132)
Efficient and highly selective covalent labeling of the estrogen receptor with [3H]tamoxifen aziridine. (1983) (130)
Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. (2007) (129)
The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype. (2005) (129)
Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: antiestrogen selectivity and promoter dependence. (1994) (128)
Estrogen receptor β ligands: Recent advances and biomedical applications (2011) (128)
Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. (1999) (128)
Characterization and quantitation of antiestrogen binding sites in estrogen receptor-positive and -negative human breast cancer cell lines. (1983) (127)
Characterization of the biological roles of the estrogen receptors, ERalpha and ERbeta, in estrogen target tissues in vivo through the use of an ERalpha-selective ligand. (2002) (127)
Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection. (2010) (125)
Physical properties of estrogen receptor complexes in MCF-7 human breast cancer cells. Differences with anti-estrogen and estrogen. (1982) (124)
Estrogen-occupied Estrogen Receptor Represses Cyclin G2 Gene Expression and Recruits a Repressor Complex at the Cyclin G2 Promoter* (2006) (123)
Extranuclear estrogen receptor-α stimulates NeuroD1 binding to the insulin promoter and favors insulin synthesis (2010) (123)
Differential DNA-binding abilities of estrogen receptor occupied with two classes of antiestrogens: studies using human estrogen receptor overexpressed in mammalian cells. (1991) (122)
A repressive role for prohibitin in estrogen signaling. (2008) (122)
Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: a comparison of the effects of cyclic adenosine 3',5'-monophosphate, estradiol, insulin-like growth factor-I, and serum factors. (1994) (121)
Powerful dominant negative mutants of the human estrogen receptor. (1993) (121)
Antiestrogens: Mechanisms and actions in target cells (1995) (119)
Estrogen receptor subtype-selective ligands: asymmetric synthesis and biological evaluation of cis- and trans-5,11-dialkyl- 5,6,11, 12-tetrahydrochrysenes. (1999) (118)
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance (2018) (118)
Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis (2015) (115)
Human estrogen receptor mutants with altered estrogen and antiestrogen ligand discrimination. (1992) (114)
Activation of estrogen receptor β is a prerequisite for estrogen‐dependent upregulation of nitric oxide synthases in neonatal rat cardiac myocytes (2001) (113)
Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. (1999) (113)
Antiestrogen basicity--activity relationships: a comparison of the estrogen receptor binding and antiuterotrophic potencies of several analogues of (Z)-1,2-diphenyl-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-butene (tamoxifen, Nolvadex) having altered basicity. (1982) (113)
Progesterone receptor regulation in T47D human breast cancer cells: analysis by density labeling of progesterone receptor synthesis and degradation and their modulation by progestin. (1988) (112)
Lipophilic impurities, not phenolsulfonphthalein, account for the estrogenic activity in commercial preparations of phenol red. (1988) (112)
Identification of Amino Acids in the Hormone Binding Domain of the Human Estrogen Receptor Important in Estrogen Binding* (1996) (110)
Genomic Collaboration of Estrogen Receptor α and Extracellular Signal-Regulated Kinase 2 in Regulating Gene and Proliferation Programs (2010) (110)
Endocrine treatment in breast cancer: Cure, resistance and beyond. (2016) (110)
Antiestrogens: Mechanisms of action and resistance in breast cancer (1997) (105)
Antagonists selective for estrogen receptor alpha. (2002) (105)
Alteration of Large-Scale Chromatin Structure by Estrogen Receptor (2002) (105)
Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) alpha activity by ERbeta in the uterus. (2003) (102)
Genetic Deletion of the Repressor of Estrogen Receptor Activity (REA) Enhances the Response to Estrogen in Target Tissues In Vivo (2005) (102)
Estrogen Receptor Regulation of the Na+/H+ Exchanger Regulatory Factor. (1999) (100)
Prothymosin Alpha Selectively Enhances Estrogen Receptor Transcriptional Activity by Interacting with a Repressor of Estrogen Receptor Activity (2000) (99)
Estrone interaction with the rat uterus: in vitro response and nuclear uptake. (1973) (98)
Molecular basis for the subtype discrimination of the estrogen receptor-beta-selective ligand, diarylpropionitrile. (2003) (97)
The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells (2014) (96)
Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. (1996) (95)
Identification of cysteine 530 as the covalent attachment site of an affinity-labeling estrogen (ketononestrol aziridine) and antiestrogen (tamoxifen aziridine) in the human estrogen receptor. (1989) (95)
Antiestrogen resistance: mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy. (1991) (95)
Mechanisms enforcing the estrogen receptor β selectivity of botanical estrogens (2013) (94)
Estrogen down-regulation of the corepressor N-CoR: mechanism and implications for estrogen derepression of N-CoR-regulated genes. (2005) (92)
Characterization of the estrogen receptor and its dynamics in MCF-7 human breast cancer cells using a covalently attaching antiestrogen. (1984) (91)
A comparative study of antiestrogen action: temporal patterns of antagonism of estrogen stimulated uterine growth and effects on estrogen receptor levels. (1977) (89)
Allosteric Control of Ligand Selectivity between Estrogen Receptors α and β - Implications for Other Nuclear Receptors (2004) (89)
Human endometrial cells in primary tissue culture: modulation of the progesterone receptor level by natural and synthetic estrogens in vitro. (1981) (89)
Anti-estrogen interaction with uterine estrogen receptors. Studies with a radiolabeled anti-estrogen (CI-628). (1978) (88)
Mutagenesis of cysteines in the hormone binding domain of the human estrogen receptor. Alterations in binding and transcriptional activation by covalently and reversibly attaching ligands. (1991) (88)
Responses to Pure Antiestrogens (ICI 164384, ICI182780) in Estrogen‐Sensitive and‐Resistant Experimental and Clinical Breast Cancer a (1995) (86)
The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor α modulation, uncoupling nuclear and membrane activation (2014) (85)
Dynamics of estrogen receptor turnover in uterine cells in vitro and in uteri in vivo. (1986) (83)
Determinants of Ligand Specificity of Estrogen Receptor-α: Estrogen versus Androgen Discrimination* (1998) (83)
Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes. (1997) (83)
Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects (2010) (82)
Facile geometric isomerization of phenolic non-steroidal estrogens and antiestrogens: limitations to the interpretation of experiments characterizing the activity of individual isomers. (1985) (82)
Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity (2017) (81)
Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-alpha and estrogen receptor-beta: correlations with biological character and distinct differences among SRC coactivator family members. (2000) (80)
Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis (2011) (80)
Analysis of Mechanisms That Determine Dominant Negative Estrogen Receptor Effectiveness (*) (1995) (80)
Different Residues of the Human Estrogen Receptor Are Involved in the Recognition of Structurally Diverse Estrogens and Antiestrogens* (1997) (78)
Bridged bicyclic cores containing a 1,1-diarylethylene motif are high-affinity subtype-selective ligands for the estrogen receptor. (2003) (78)
Estrogen regulation of human osteoblast function is determined by the stage of differentiation and the estrogen receptor isoform (2001) (78)
Mechanisms of Action and Cross-Talk Between Estrogen Receptor and Progesterone Receptor Pathways (2000) (78)
The roles of membrane estrogen receptor subtypes in modulating dopamine transporters in PC‐12 cells (2008) (77)
Hormone induction of progesterone receptor (PR) messenger ribonucleic acid and activation of PR promoter regions in ovarian granulosa cells: evidence for a role of cyclic adenosine 3',5'-monophosphate but not estradiol. (1998) (77)
Triarylpyrazoles with basic side chains: development of pyrazole-based estrogen receptor antagonists. (2001) (77)
Androgen-uterine interactions: An assessment of androgen interaction with the testosterone- and estrogen-receptor systems and stimulation of uterine growth and progesterone-receptor synthesis (1979) (76)
Involvement of cyclic AMP response element binding protein (CREB) and estrogen receptor phosphorylation in the synergistic activation of the estrogen receptor by estradiol and protein kinase activators (2001) (76)
Cyclin D1 Antagonizes BRCA1 Repression of Estrogen Receptor α Activity (2005) (74)
Caveolin-1 potentiates estrogen receptor alpha (ERalpha) signaling. caveolin-1 drives ligand-independent nuclear translocation and activation of ERalpha. (1999) (74)
Identification of charged residues in an N-terminal portion of the hormone-binding domain of the human estrogen receptor important in transcriptional activity of the receptor. (1993) (72)
Hormone binding and transcription activation by estrogen receptors: Analyses using mammalian and yeast systems (1993) (72)
Design of pathway preferential estrogens that provide beneficial metabolic and vascular effects without stimulating reproductive tissues (2016) (71)
Transcription Activation by the Human Estrogen Receptor Subtypeβ (ERβ) Studied with ERβ and ERα Receptor Chimeras* *This work was supported by NIH Grants CA-18119 and CA-60514 (to B.S.K.). (1998) (71)
CHAPTER 7 – Estrogen Actions on Syntheses of Macromolecules in Target Cells (1975) (70)
Alterations in Transforming Growth Factor-α and -β Production and Cell Responsiveness during the Progression of MCF-7 Human Breast Cancer Cells to Estrogen-Autonomous Growth (1994) (70)
Human estrogen receptor beta-specific monoclonal antibodies: characterization and use in studies of estrogen receptor beta protein expression in reproductive tissues (2001) (69)
Differential regulation of gene expression by estrogen in estrogen growth-independent and -dependent MCF-7 human breast cancer cell sublines. (1991) (69)
Estrogen Receptor Alpha Represses Transcription of Early Target Genes via p300 and CtBP1 (2009) (69)
Activation of transcriptionally inactive human estrogen receptors by cyclic adenosine 3',5'-monophosphate and ligands including antiestrogens. (1994) (68)
Distinctive actions of membrane-targeted versus nuclear localized estrogen receptors in breast cancer cells. (2005) (67)
Regulation of Nuclear Receptor Transcriptional Activity by a Novel DEAD Box RNA Helicase (DP97)* (2003) (66)
Synergistic Activation of the Serotonin-1A Receptor by Nuclear Factor-κB and Estrogen (2001) (66)
Elemental isomerism: a boron-nitrogen surrogate for a carbon-carbon double bond increases the chemical diversity of estrogen receptor ligands. (2007) (65)
Characterization of estrogen and progesterone receptors and the dissociated regulation of growth and progesterone receptor stimulation by estrogen in MDA-MB-134 human breast cancer cells. (1986) (65)
Molecular Cloning of Porcine Estrogen Receptor-β Complementary DNAs and Developmental Expression in Periimplantation Embryos1 (2002) (65)
Adenovirus-mediated delivery of a dominant negative estrogen receptor gene abrogates estrogen-stimulated gene expression and breast cancer cell proliferation. (1999) (65)
Interaction of a high affinity anti-estrogen (alpha-[4-pyrrolidinoethoxy]phenyl-4-hydroxy-alpha'-nitrostilbene, CI628M) with uterine estrogen receptors. (1981) (64)
Hormone-dependent cancer (1996) (64)
A new actor in the estrogen receptor drama--enter ER-beta. (1997) (63)
Estrogen regulation of the glucuronidation enzyme UGT2B15 in estrogen receptor-positive breast cancer cells. (2006) (63)
Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen (1996) (62)
Estrogen receptor regulation of the Na+/H+ exchange regulatory factor. (1999) (62)
Ontogeny of uterine responsiveness to estrogen during early development in the rat. (1974) (61)
Regulation of keratin 19 gene expression by estrogen in human breast cancer cells and identification of the estrogen responsive gene region (2000) (61)
Uterine plasminogen activator activity: modulation by steroid hormones. (1982) (61)
Structure‐Function Relationships in Estrogen Receptors and the Characterization of Novel Selective Estrogen Receptor Modulators with Unique Pharmacological Profiles (2001) (60)
Human endometrial cells in primary tissue culture: estrogen interactions and modulation of cell proliferation. (1978) (60)
Isocoumarins as estrogen receptor beta selective ligands: Isomers of isoflavone phytoestrogens and their metabolites. (2005) (59)
Phosphorylation by p38 Mitogen-Activated Protein Kinase Promotes Estrogen Receptor α Turnover and Functional Activity via the SCFSkp2 Proteasomal Complex (2012) (59)
Fundamental differences in the action of estrogens and antiestrogens on the uterus: comparison between compounds with similar duration of action. (1977) (58)
Antagonism of development and growth of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by the antiestrogen U 23,469 and effects on estrogen and progesterone receptors. (1977) (58)
Non-nuclear-initiated actions of the estrogen receptor protect cortical bone mass. (2013) (58)
Integrative genomics of gene and metabolic regulation by estrogen receptors α and β, and their coregulators (2013) (58)
Progesterone modulation of estrogen-stimulated uterine biosynthetic events and estrogen receptor levels (1977) (58)
Estrogenic diazenes: heterocyclic non-steroidal estrogens of unusual structure with selectivity for estrogen receptor subtypes. (2003) (57)
Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity. (2005) (57)
Novel Roles for ERK5 and Cofilin as Critical Mediators Linking ERα-Driven Transcription, Actin Reorganization, and Invasiveness in Breast Cancer (2014) (56)
An evaluation of the involvement of polyamines in modulating MCF-7 human breast cancer cell proliferation and progesterone receptor levels by estrogen and antiestrogen. (1987) (56)
Selective recognition of distinct classes of coactivators by a ligand-inducible activation domain. (2004) (56)
Transcriptional regulation of the human quinone reductase gene by antiestrogen-liganded estrogen receptor-alpha and estrogen receptor-beta. (1998) (56)
Synthesis and evaluation of estrogen receptor ligands with bridged oxabicyclic cores containing a diarylethylene motif: estrogen antagonists of unusual structure. (2005) (56)
Highly Sensitive Quantitative Imaging for Monitoring Single Cancer Cell Growth Kinetics and Drug Response (2014) (56)
Biomedicine. Defining the "S" in SERMs. (2002) (55)
Synthesis and inducibility of the Uterine estrogen-induced protein, IP, during the rat estrous cycle: clues to uterine estrogen sensitivity. (1975) (55)
Characterization of the subunit nature of nuclear estrogen receptors by chemical cross-linking and dense amino acid labeling. (1985) (54)
Androgen-uterine interaction: nuclear translocation of the estrogen receptor and induction of the synthesis of the uterine-induced protein (IP) by high concentrations of androgens in vitro but not in vivo. (1976) (53)
An assessment of the role of domain F and pest sequences in estrogen receptor half-life and bioactivity (1993) (52)
Directed Evolution of Human Estrogen Receptor Variants with Significantly Enhanced Androgen Specificity and Affinity* (2004) (52)
Biology and receptor interactions of estriol and estriol derivatives in vitro and in vivo. (1984) (52)
Antiestrogens: studies using an in vitro estrogen-responsive uterine system. (1973) (50)
Structural requirements for high affinity ligand binding by estrogen receptors: a comparative analysis of truncated and full length estrogen receptors expressed in bacteria, yeast, and mammalian cells. (1992) (50)
Protein kinase A activation of estrogen receptor alpha transcription does not require proteasome activity and protects the receptor from ligand-mediated degradation. (2004) (49)
Non-nuclear estrogen receptor alpha activation in endothelium reduces cardiac ischemia-reperfusion injury in mice. (2017) (49)
Transcriptomic analysis identifies gene networks regulated by estrogen receptor α (ERα) and ERβ that control distinct effects of different botanical estrogens (2014) (49)
Activation of ERα is necessary for estradiol's anorexigenic effect in female rats (2010) (49)
Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells (1999) (49)
Macrophage-Elicited Loss of Estrogen Receptor Alpha in Breast Cancer Cells via Involvement of MAPK and c-Jun at the ESR1 Genomic Locus (2011) (48)
Antiestrogen pharmacology and mechanism of action. (1983) (47)
Estrogen receptor inducibility of the human Na+/H+ exchanger regulatory factor/ezrin-radixin-moesin binding protein 50 (NHE-RF/EBP50) gene involving multiple half-estrogen response elements. (2002) (47)
Antiestrogen stimulation of the production of a 37,000 molecular weight secreted protein and estrogen stimulation of the production of a 32,000 molecular weight secreted protein in MCF-7 human breast cancer cells. (1987) (47)
Dietary licorice root supplementation reduces diet-induced weight gain, lipid deposition, and hepatic steatosis in ovariectomized mice without stimulating reproductive tissues and mammary gland. (2016) (46)
Modulation of estrogen receptor activity by selective coregulators (2003) (46)
Regulation of pS2 gene expression by affinity labeling and reversibly binding estrogens and antiestrogens: comparison of effects on the native gene and on pS2-chloramphenicol acetyltransferase fusion genes transfected into MCF-7 human breast cancer cells. (1988) (46)
Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs). (2010) (46)
Progesterone receptor synthesis and degradation in MCF-7 human breast cancer cells as studied by dense amino acid incorporation. Evidence for a non-hormone binding receptor precursor. (1986) (46)
Acyclic amides as estrogen receptor ligands: synthesis, binding, activity and receptor interaction. (2000) (45)
Comparative effects of estrogen and antiestrogen on plasma renin substrate levels and hepatic estrogen receptors in the rat. (1981) (45)
The anticancer potential of steroidal saponin, dioscin, isolated from wild yam (Dioscorea villosa) root extract in invasive human breast cancer cell line MDA-MB-231 in vitro. (2016) (44)
Predominant Role of Nuclear Versus Membrane Estrogen Receptor α in Arterial Protection: Implications for Estrogen Receptor α Modulation in Cardiovascular Prevention/Safety (2018) (44)
Full Antagonism of the Estrogen Receptor without a Prototypical Ligand Side Chain (2016) (44)
Estrogen Receptor Isoform‐Specific Induction of Progesterone Receptors in Human Osteoblasts (2002) (44)
OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells (2016) (44)
Haploinsufficiency of the corepressor of estrogen receptor activity (REA) enhances estrogen receptor function in the mammary gland (2006) (43)
ERα and ERβ expression and transcriptional activity are differentially regulated by HDAC inhibitors (2006) (43)
Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds (2019) (43)
Licorice root components in dietary supplements are selective estrogen receptor modulators with a spectrum of estrogenic and anti-estrogenic activities (2016) (43)
Estrogenic effects of extracts from cabbage, fermented cabbage, and acidified brussels sprouts on growth and gene expression of estrogen-dependent human breast cancer (MCF-7) cells. (2000) (43)
Non-estrogenic Xanthohumol Derivatives Mitigate Insulin Resistance and Cognitive Impairment in High-Fat Diet-induced Obese Mice (2018) (43)
The nature of the ligand-binding pocket of estrogen receptor alpha and beta: The search for subtype-selective ligands and implications for the prediction of estrogenic activity (2003) (42)
Analogs of methyl-piperidinopyrazole (MPP): antiestrogens with estrogen receptor alpha selective activity. (2009) (42)
Mechanisms of action and cross-talk between estrogen receptor and progesterone receptor pathways. (2000) (42)
Distribution of the oestrogen-induced protein and of total protein between endometrial and myometrial fractions of the immature and mature rat uterus. (1974) (42)
Some properties of silkmoth moulting gel and moulting fluid (1970) (42)
Estrogen Receptor-β Modulation of the ERα-p53 Loop Regulating Gene Expression, Proliferation, and Apoptosis in Breast Cancer (2017) (42)
Progesterone antagonism of estradiol-stimulated uterine ‘induced protein’ synthesis (1977) (42)
Characterization of a temperature-sensitive mutation in the hormone binding domain of the human estrogen receptor. Studies in cell extracts and intact cells and their implications for hormone-dependent transcriptional activation. (1992) (42)
Repression of endogenous estrogen receptor activity in MCF-7 human breast cancer cells by dominant negative estrogen receptors. (1995) (41)
An evaluation of the role of antiestrogen-binding sites in mediating the growth modulatory effects of antiestrogens: studies using t-butylphenoxyethyl diethylamine, a compound lacking affinity for the estrogen receptor. (1985) (41)
Estrogen receptor mutants which do not bind 17 beta-estradiol dimerize and bind to the estrogen response element in vivo. (1995) (40)
Structural analysis of covalently labeled estrogen receptors by limited proteolysis and monoclonal antibody reactivity. (1987) (40)
Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells. (1984) (39)
ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors. (2006) (39)
Allosteric control of ligand selectivity between estrogen receptors alpha and beta: implications for other nuclear receptors. (2004) (39)
The Activation Function-1 of Estrogen Receptor Alpha Prevents Arterial Neointima Development Through a Direct Effect on Smooth Muscle Cells (2015) (39)
Aryl hydrocarbon receptor modulation of estrogen receptor α-mediated gene regulation by a multimeric chromatin complex involving the two receptors and the coregulator RIP140. (2012) (39)
Iodohexestrols. II. Characterization of the binding and estrogenic activity of iodinated hexestrol derivatives, in vitro and in vivo. (1975) (39)
Integration of Molecular Profiling and Chemical Imaging to Elucidate Fibroblast-Microenvironment Impact on Cancer Cell Phenotype and Endocrine Resistance in Breast Cancer (2014) (38)
Cross-linking of estrogen receptor to chromatin in intact MCF-7 human breast cancer cells: optimization and effect of ligand. (1990) (38)
Biological potency and uterine estrogen receptor interactions of the metabolites of the antiestrogens CI628 and U23,469. (1981) (38)
The Effects of the Phytoestrogen, Coumestrol, on Gonadotropin‐Releasing Hormone (GnRH) mRNA Expression in GT1‐7 GnRH Neurones (2003) (37)
The estrogen receptor: a structure-based approach to the design of new specific hormone-receptor combinations. (2001) (37)
Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors. (2017) (37)
Estrogen receptor-mediated transcription involves the activation of multiple kinase pathways in neuroblastoma cells (2014) (37)
Furans with basic side chains: synthesis and biological evaluation of a novel series of antagonists with selectivity for the estrogen receptor alpha. (2001) (37)
Thyroid hormone can increase estrogen-mediated transcription from a consensus estrogen response element in neuroblastoma cells. (2005) (37)
General esterases of silkmoth moulting fluid: Preliminary characterization (1971) (36)
Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells (2009) (36)
MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression (2017) (35)
Proteinases of silkmoth moulting fluid: Physical and catalytic properties (1971) (35)
New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons. (2018) (35)
Regulation of Prothymosin α Gene Expression by Estrogen in Estrogen Receptor-Containing Breast Cancer Cells via Upstream Half-Palindromic Estrogen Response Element Motifs. (2001) (34)
Structure-guided optimization of estrogen receptor binding affinity and antagonist potency of pyrazolopyrimidines with basic side chains. (2007) (34)
Antiprogestin-receptor complexes: differences in the interaction of the antiprogestin RU38,486 and the progestin R5020 with the progesterone receptor of human breast cancer cells. (1986) (34)
Plasminogen activators in tissues of the immature and estrogen-stimulated rat uterus and in uterine luminal fluid: characterization and properties. (1983) (34)
Identification of two cysteines closely positioned in the ligand-binding pocket of the human estrogen receptor: roles in ligand binding and transcriptional activation. (1992) (33)
Effects of the sex steroid hormones and vitamin D3 on calcium-binding proteins in the chick shell gland. (1979) (33)
Estrogen-regulated prohibitin is required for mouse uterine development and adult function. (2011) (33)
Antiestrogen action in the medial basal hypothalamus and pituitary of immature female rats: insights concerning relationships among estrogen, dopamine, and prolactin. (1986) (33)
Efficient and selective photoaffinity labeling of the estrogen receptor using two nonsteroidal ligands that embody aryl azide or tetrafluoroaryl azide photoreactive functions. (1991) (33)
Localization of estrogen receptors in uterine cells. An appraisal of translocation. (1979) (32)
Synergistic activation of the serotonin-1A receptor by nuclear factor-kappa B and estrogen. (2001) (32)
A MicroRNA196a2* and TP63 Circuit Regulated by Estrogen Receptor-α and ERK2 that Controls Breast Cancer Proliferation and Invasiveness Properties (2012) (32)
Lipin1 regulation by estrogen in uterus and liver: implications for diabetes and fertility. (2007) (32)
Determinants for the repression of estrogen receptor transcriptional activity by ligand-occupied progestin receptors (1997) (31)
Observations arising from the use of pure antioestrogens on oestrogen-responsive (MCF-7) and oestrogen growth-independent (K3) human breast cancer cells (1995) (31)
William L. McGuire Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer. (1997) (29)
The Androgen Derivative 5 A -Androstane-3 B ,17 B -Diol Inhibits Prostate Cancer Cell Migration Through Activation of the Estrogen Receptor B Subtype (2005) (28)
Antiestrogens and antiestrogen metabolites: preparation of tritium-labeled (+/-)-cis-3-[p-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-naphthyl)phenoxyl]-1,2-propanediol (U-23469) and characterization and synthesis of a biologically important metabolite. (1979) (28)
Repressor of estrogen receptor activity (REA) is essential for mammary gland morphogenesis and functional activities: studies in conditional knockout mice. (2011) (27)
Affinity labeling of receptors for steroid and thyroid hormones. (1984) (27)
Stilbestrols and stilbestrol derivatives: Estrogenic potency and temporal relationships between estrogen receptor binding and uterine growth (1978) (27)
Tamoxifen aziridines: effective inactivators of the estrogen receptor. (1981) (26)
Estrogen Receptor-KRAB Chimeras Are Potent Ligand-dependent Repressors of Estrogen-regulated Gene Expression* (2000) (26)
Differential estradiol and selective estrogen receptor modulator (SERM) regulation of Keratin 13 gene expression and its underlying mechanism in breast cancer cells (2008) (25)
Uterine development and fertility are dependent on gene dosage of the nuclear receptor coregulator REA. (2012) (25)
Bibenzyl- and stilbene-core compounds with non-polar linker atom substituents as selective ligands for estrogen receptor beta. (2009) (25)
Characterization and regulation of estrogen and progesterone receptors in breast cancer. (1992) (24)
Inactive proteinases in silkmoth moulting gel (1971) (24)
Dissociated regulation of growth and ornithine decarboxylase activity by estrogen in the rat uterus. (1984) (24)
Biological activity and receptor binding of a strongly interacting estrogen in human breast cancer cells. (1984) (24)
Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells. (1985) (24)
Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells. (2017) (24)
Nonnuclear Estrogen Receptor Activation Improves Hepatic Steatosis in Female Mice. (2016) (23)
Regulation of prothymosin alpha gene expression by estrogen in estrogen receptor-containing breast cancer cells via upstream half-palindromic estrogen response element motifs. (2001) (23)
Antiestrogen action in breast cancer cells: Modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites (1985) (23)
Antiestrogen modulation of the growth and properties of ovarian-autonomous and ovarian-dependent mammary tumors in rats. (1979) (23)
Monoaryl-substituted salicylaldoximes as ligands for estrogen receptor beta. (2008) (23)
A transcriptionally active estrogen receptor mutant is a novel type of dominant negative inhibitor of estrogen action. (1996) (22)
Analysis of Estrogen Response Element Binding by Genetically Selected Steroid Receptor DNA Binding Domain Mutants Exhibiting Altered Specificity and Enhanced Affinity* (1999) (22)
14-3-3ζ as a predictor of early time to recurrence and distant metastasis in hormone receptor-positive and -negative breast cancers (2013) (22)
The estrogen-regulated transcription factor PITX1 coordinates gene-specific regulation by estrogen receptor-alpha in breast cancer cells. (2011) (22)
Identification of a novel transferable cis element in the promoter of an estrogen-responsive gene that modulates sensitivity to hormone and antihormone. (1997) (22)
Estrogen receptor-α and aryl hydrocarbon receptor involvement in the actions of botanical estrogens in target cells (2016) (21)
Metabolite ligands of estrogen receptor-beta reduce primate coronary hyperreactivity. (2006) (21)
Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer (2020) (21)
Relationships among uterine growth, ornithine decarboxylase activity and polyamine levels: studies with estradiol and antiestrogens (1984) (21)
Estrogen receptor transformation in MCF-7 breast cancer cells: characterization by immunochemical and sedimentation analyses. (1984) (21)
Highly Selective Salicylketoxime-Based Estrogen Receptor β Agonists Display Antiproliferative Activities in a Glioma Model (2015) (20)
17 alpha (haloacetamidoalkyl) estradiols alkylate the human estrogen receptor at cysteine residues 417 and 530. (1997) (20)
Alterations in transforming growth factor-alpha and -beta production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. (1994) (19)
Estrogen regulation of proliferation and hormonal modulation of estrogen and progesterone receptor biosynthesis and degradation in target cells. (1990) (19)
Selective Nonnuclear Estrogen Receptor Activation Decreases Stroke Severity and Promotes Functional Recovery in Female Mice. (2018) (19)
Integrative genomics of gene and metabolic regulation by estrogen receptors α and β, and their coregulators (2017) (18)
Estrogenic affinity labels: synthesis, irreversible receptor binding, and bioactivity of aziridine-substituted hexestrol derivatives. (1987) (18)
Plasminogen activators in human breast cancer cell lines: hormonal regulation and properties. (1988) (18)
The stability of the uterine estrogen receptor when complexed with estrogens or antiestrogens. (1980) (18)
Bivalent ligands as probes of estrogen receptor action (1994) (18)
Estrogen and antiestrogen action: studies in reproductive target tissues and tumors. (1979) (18)
Estrogen receptors of human endometrium: characterization of nuclear and cytoplasmic forms and comparisons with rat uterine receptors. (1980) (18)
Estrogen receptor regulation of quinone reductase in breast cancer: implications for estrogen-induced breast tumor growth and therapeutic uses of tamoxifen. (2005) (18)
Corrigendum: NFκB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses (2008) (17)
Novel estrogen receptor ligands based on an anthranylaldoxime structure: role of the phenol-type pseudocycle in the binding process. (2003) (16)
Estrogenic potency, receptor interactions, and metabolism of catechol estrogens in the immature rat uterus in vitro. (1982) (16)
Synthesis and biological evaluation of a novel series of furans: ligands selective for estrogen receptor alpha. (2001) (16)
Antitumor activities and estrogen receptor interactions of the metabolites of the antiestrogens C1628 and U23,469 in the 7,12-dimethylbenz(a)anthracene-induced rat mammary tumor system. (1981) (15)
Distinct roles for AF-1 and -2 of ER-alpha in regulation of MMP-13 promoter activity. (2009) (15)
A human estrogen receptor (ER)alpha mutation with differential responsiveness to nonsteroidal ligands: novel approaches for studying mechanism of ER action. (2008) (15)
Estrogens and androgens inhibit association of RANKL with the pre‐osteoblast membrane through post‐translational mechanisms (2017) (15)
The coregulator, repressor of estrogen receptor activity (REA), is a crucial regulator of the timing and magnitude of uterine decidualization. (2013) (15)
Suppression of Tumor Growth, Metastasis, and Signaling Pathways by Reducing FOXM1 Activity in Triple Negative Breast Cancer (2020) (14)
Multiple Beneficial Roles of Repressor of Estrogen Receptor Activity (REA) in Suppressing the Progression of Endometriosis. (2016) (14)
Effects of gonadal hormones on calcium-binding protein in chick duodenum. (1979) (14)
Estrogen-induced CCN1 is critical for establishment of endometriosis-like lesions in mice. (2014) (13)
Anti-estrogen Interaction with Uterine Estrogen Receptors (1979) (13)
Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas. (2005) (13)
The capacity of the antiestrogen CI-628 to activate the estrogen receptor in vitro. (1981) (13)
An evaluation of the interactions of antiestrogens with pituitary and striatal dopamine receptors. (1987) (12)
Differential utilization of nuclear and extranuclear receptor signaling pathways in the actions of estrogens, SERMs, and a tissue-selective estrogen complex (TSEC) (2016) (10)
Uterine estrogen-induced protein: physical and immunological comparison with ovalbumin. (1974) (10)
Estrogen receptors: Ligand discrimination and antiestrogen action (2004) (9)
Comparative effects of estrogen and antiestrogens on enzyme activities in R3230AC rat mammary tumors and uteri of tumor-bearing animals. (1980) (9)
Corrigendum to: Integrative genomics of gene and metabolic regulation by estrogen receptors and, and their coregulators (Molecular Systems Biology, (2014), 9, 1, (676), 10.1038/msb.2013.28) (2017) (9)
The tissue-specific effects of different 17β-estradiol doses reveal the key sensitizing role of AF1 domain in ERα activity (2020) (9)
Comparative analysis of estrogen receptors covalently labeled with an estrogen and an antiestrogen in several estrogen target cells as studied by limited proteolysis. (1988) (9)
Protective Hematopoietic Effect of Estrogens in a Mouse Model of Thrombosis: Respective Roles of Nuclear Versus Membrane Estrogen Receptor α. (2015) (8)
Ketononestrol aziridine, an agonistic estrogen receptor affinity label: study of its bioactivity and estrogen receptor covalent labeling. (1987) (8)
Dual-mechanism estrogen receptor inhibitors (2021) (8)
Biological activities of tamoxifen aziridine, an antiestrogen-based affinity label for the estrogen receptor, in vivo and in vitro. (1985) (8)
Methods for assessing estrogen effects on new uterine protein synthesis in vitro. (1975) (8)
DNA Shuffling Method for Generating Estrogen Receptor α and β Chimeras in Yeast (2003) (8)
[125I]Iododesethyl tamoxifen aziridine: Synthesis and covalent labeling of the estrogen receptor with an iodine-labeled affinity label (1986) (8)
Ligand Accessibility and Bioactivity of a Hormone-Dendrimer Conjugate Depend on pH and pH History. (2015) (8)
Evaluation of wild yam (Dioscorea villosa) root extract as a potential epigenetic agent in breast cancer cells (2013) (7)
Targeting metabolic adaptations in the breast cancer–liver metastatic niche using dietary approaches to improve endocrine therapy efficacy (2021) (7)
Estrogen-receptor movement to the nucleus: discussion of a cytoplasmic-exclusion hypothesis. (1976) (7)
ANTIESTROGEN BASICITY‐ACTIVITY RELATIONSHIPS: A COMPARISON OF THE ESTROGEN RECEPTOR BINDING AND ANTIUTEROTROPHIC POTENCIES OF SEVERAL ANALOGS OF (Z)‐1,2‐DIPHENYL‐1‐(4‐(2‐(DIMETHYLAMINO)ETHOXY)PHENYL)‐1‐BUTENE (TAMOXIFEN, NOLVADEX) HAVING ALTERED BASICITY (1982) (7)
Combined Targeting of Estrogen Receptor Alpha and Exportin 1 in Metastatic Breast Cancers (2020) (7)
The intranuclear distribution of rat uterine estrogen receptors determined after nuclease treatment and chromatin fractionation (1982) (7)
FOXM1 regulates glycolysis and energy production in multiple myeloma (2022) (7)
Considerations in the design and evaluation of cytotoxic estrogens (1982) (6)
Phenethyl pyridines with non-polar internal substituents as selective ligands for estrogen receptor beta. (2009) (6)
Respective role of membrane and nuclear estrogen receptor (ER) α in the mandible of growing mice: Implications for ERα modulation (2018) (6)
Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain. (2018) (6)
Modulation of progestin binding activity in cultured human breast carcinoma cells: the effect of serum type and concentration. (1983) (6)
Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors (2020) (5)
Nitrosourea and nitrosocarbamate derivatives of the antiestrogen tamoxifen as potential estrogen receptor-mediated cytotoxic agents in human breast cancer cells (2005) (5)
Mechanisms of estrogen and antiestrogen action in mammary cancer. (1981) (5)
William L. McGuire Memorial Symposium. Estrogen receptors: ligand discrimination and antiestrogen action. (1993) (4)
Salicylaldoximes and anthranylaldoximes as alternatives to phenol-based estrogen receptor ligands (2006) (4)
Endogenous DOPA inhibits melanoma through suppression of CHRM1 signaling. (2022) (4)
Publisher Correction: Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance (2018) (4)
Estrogen Receptor Beta 1: A Potential Therapeutic Target for Female Triple Negative Breast Cancer. (2022) (3)
Human endometrial cells in primary tissue culture: Modulation of progesterone receptor level by estrogens in vitro (1980) (3)
Erratum: Pyrazolo[1.5-a]pyrimidines: Estrogen receptor ligands possessing estrogen receptor β antagonist activity (Journal of Medicinal Chemistry (2004) 47 (5877)) (2005) (3)
Transcription Regulation and Genome Rewiring Governing Sensitivity and Resistance to FOXM1 Inhibition in Breast Cancer (2021) (3)
Dissociated regulation of growth and progesterone receptor stimulation by estrogen in MDA-MB-134 human breast cancer cells (1985) (2)
The Androgen Derivative 5alpha-androstane-3beta,17beta-diol (3beta-Adiol) Inhibits Prostate Cancer Cell Migration through Activation of the Estrogen Receptor beta. (2005) (2)
Pathway Preferential Estrogens Prevent Hepatosteatosis Due to Ovariectomy and High-Fat Diets (2021) (2)
DNA shuffling method for generating estrogen receptor alpha and beta chimeras in yeast. (2003) (2)
Estrogen Receptors (cid:1) and (cid:2) as Determinants of Gene Expression: Influence of Ligand, Dose, and Chromatin Binding (2008) (2)
Corrigendum to “Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity” [Mol. Cell Endocrinol. 440 (2016) 138–150] (2017) (2)
Defining the Energetic Basis for a Conformational Switch Mediating Ligand-Independent Activation of Mutant Estrogen Receptors in Breast Cancer (2021) (2)
Chromatin , Gene , and RNA Regulation NovelRoles forERK 5 andCo fi lin asCriticalMediatorsLinking ER a-Driven Transcription , Actin Reorganization , and Invasiveness in Breast Cancer (2014) (1)
Characterization of Estrogen Receptors and Biological Responses to Estrogen in Human Endometrium (1980) (1)
Corrigendum: Full antagonism of the estrogen receptor without a prototypical ligand side chain. (2017) (1)
Interaction of antiestrogens with estrogen receptors and antiestrogen binding sites (1984) (1)
Endocrine Society 2014 Laureate Awards (2014) (1)
New 1,1-diarylethylene FOXM1 inhibitors potently reduce intracellular FOXM1 and suppress high-grade serous ovarian carcinoma cell viability (2022) (1)
Structure by Estrogen Receptor Alteration of Large-Scale Chromatin (2002) (1)
Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds (2019) (1)
Derivation and analysis of a lag-decay model for protein turnover involving a biosynthetic precursor (1986) (1)
Functional interactions between cyclin D1 and BRCA1 determine activity of ligand-bound estrogen receptor alpha (2002) (0)
Characterization of salt-extracted nuclear antiestr0gen receptor complexes (1984) (0)
Abstract 434: Identification of 14-3-3α as a predictor of early time to recurrence and a molecular target in metastatic hormone receptor-positive and -negative breast cancers (2012) (0)
Hormone-dependent cancer Edited by Jorge R. Pasqualini and Benita S. Katzenellenbogen. Published April 1996 by Marcel Dekker Inc. 579 pp. ISBN: 0-8247-9697-7. Price: US$ 175.00 (1996) (0)
Human Estrogen Receptor alpha Ligand-binding Domain in Complex with (R,R)-5,11-cis-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol and a Glucocorticoid Receptor Interacting Protein 1 NR box II Peptide (2002) (0)
Crystal Structure of Estrogen Receptor Alpha mutant 537S Complexed with 4-(6-hydroxy-1H-indazol-3-yl)benzene-1,3-diol (2008) (0)
Analysis of the role of the transcription factor-C/EBβ in implantation (2010) (0)
The androgen derivative 5alpha-androstane-3beta,17beta-diol (3beta-Adiol) inhibits migration of prostate cancer cell by activation of the estrogen receptor beta. (2005) (0)
A tribute to Jack Gorski: estrogen receptor model builder and scientific friend to many. (1990) (0)
Abstract 3984: NB compound FOXM1 inhibitors have potent anti-cancer activity in high-grade serous ovarian carcinoma (2023) (0)
Abstract 4869: Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects (2010) (0)
Biological Activity and Receptor Binding of a Strongly Interacting Estrogen in Human Breast Cancer Cells1 (2006) (0)
Erratum: Full antagonism of the estrogen receptor without a prototypical ligand side chain. (2017) (0)
Crystal Structure of the ER-alpha Ligand-binding Domain (L372S, L536S) in complex with DMERI-30 (2021) (0)
Ligand Requirements for Estrogen Receptor Function and the Actions of Antiestrogens (1994) (0)
Abstract 5846: Extranuclear Estrogen Receptor {alpha} Signaling Promotes Endothelial Monolayer Integrity but Not Breast Cancer or Uterine Growth in Mice (2009) (0)
Dual-mechanism estrogen receptor inhibitors expand the repertoire of anti-hormone therapy for breast cancer (2020) (0)
ERKO Mice β ERKO and α : Studies with α Mediated through Stromal Estrogen Receptor Estrogen Imprinting of the Developing Prostate Gland Is Updated (2001) (0)
Abstract 4169: ERK2 functional chromatin footprints in patient-derived breast tumor cells predict molecular subtype, clinical outcome, and drug response in breast cancers (2014) (0)
Estrogens and Carcinogenicity: An Overview of Information from Studies in Experimental Animal Systems (1986) (0)
Abstract 503: Mammary fibroblasts induce hormone-independent growth in estrogen receptor-positive breast cancer cells via an epithelial-to-mesenchymal transition in a 3D cell culture model. (2013) (0)
Biological Activity and Receptor Binding of a Strongly Interacting Estrogen in Human Breast Cancer Cells 1 (2006) (0)
CHRM1 is a Druggable Melanoma Target Whose Endogenous Activity is Determined by Inherited Genetic Variation in DOPA Production (2021) (0)
ANTIESTROGENS AND ANTIESTROGEN METABOLITES: PREPARATION OF TRITIUM-LABELED (.+-.)-CIS-3-(P-(1,2,3,4-TETRAHYDRO-6-METHOXY-2-PHENYL-1-NAPHTHYL)PHENOXY)-1,2-# PROPANEDIOL AND CHARACTERIZATION AND SYNTHESIS OF A BIOLOGICALLY IMPORTANT MET (1980) (0)
Crystal Structure of Estrogen Receptor alpha Complexed to a B-N Substituted Ligand (2007) (0)
REGULATION OF ESTROGEN RECEPTOR-ALPHA MEDIATED GENE EXPRESSION AND ENDOCRINE RESISTANCE THROUGH ESTROGEN RECEPTOR-ALPHA PHOSPHORYLATION AND MICRO-RNA IN BREAST CANCER BY KYURI KIM DISSERTATION Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Molecular an (2011) (0)
Comparison with Ovalbumin (0)
Abstract 1316: Estrogen receptor-α dictates the subcellular localization of ERK5 to control differential proliferation and invasion programs of breast cancer cells. (2013) (0)
Abstract 1955: Suppression of hormone receptor-positive and triple-negative breast cancers by new inhibitors of the transcription factor FOXM1 (2018) (0)
Abstract 939: Mechanistic basis of tamoxifen-associated development of endocrine resistance in breast cancer (2011) (0)
Crystal Structure of the Estrogen Receptor Alpha Ligand Binding Domain Complexed to Burned Meat Compound PhIP (2008) (0)
OR12-07 Full Antagonism of Breast Cancer Cell Proliferation Can Result from Many Ligand-Induced Conformational Distortions of the Estrogen Receptor Ligand Binding Domain (2020) (0)
Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with an N-trifluoroethyl OBHS-N derivative (2016) (0)
Crystal Structure of the Estrogen Receptor Alpha Ligand Binding Domain Complexed to an Ether Estradiol Compound (2008) (0)
0218: The uterine and vascular actions of estetrol delineate an original distinctive profile of estrogen receptor α modulation, uncoupling nuclear and membrane activation (2014) (0)
017Membrane delimited estrogen receptor activation protects heart against ischemic-reperfusion injury in mice with cardiac but not endothelial specific ablation of ERα (2017) (0)
Publisher Correction: Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance (2018) (0)
Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression (2023) (0)
Jack Gorski (1931–2006) (2006) (0)
OR09-2 Pathway Preferential Estrogens Prevent Hepatosteatosis Due to Ovariectomy and High-Fat Diets (2019) (0)
Abstract 877: Estrogen Dendrimer Conjugate Reveals that Estrogen-induced Endothelial Cell Migration and Proliferation are Mediated by Non-nuclear Estrogen Receptors that Interact Directly with G{alpha}i (2006) (0)
Do Not Bind 17P-Estradiol Dimerize and Bind to the Estrogen Response Element in Viva (2001) (0)
CHARACTERIZATION BY IMMUNOCHEMICAL AND (1984) (0)
Abstract 999: ESR1 mutations activate and confer hormone resistance via distinct mechanisms (2017) (0)
Human Estrogen Receptor beta Ligand-binding Domain in Complex with (R,R)-5,11-cis-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol (2002) (0)
In memoriam: Jack Gorski (1931-2006). (2006) (0)
186. Synthesis and inductibility of the estrogen-induced protein (IP) in developing and mature cycling rats: Clues to uterine estrogen sensitivity (1974) (0)
Estrogen-Receptor and Antiestrogen-Receptor Complexes: Cell- and Promoter-Specific Effects and Interactions with Second Messenger Signaling Pathways (1995) (0)
Crystal Structure of Estrogen Receptor Alpha Ligand Binding Domain Mutant 537S Complexed with an Ethyl Indazole Compound (2008) (0)
Liver-specific overexpression of a constitutive active estrogen receptor alpha (ERα)-variant induces hypo lipidemia in male APOE3-leiden mice (2000) (0)
Hormones and Cancer Reviewers (2011) (0)
The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells (2014) (0)
Abstract P4-07-02: Withdrawn (2019) (0)
Antagonists Selective for Estrogen Receptor (cid:1) (2002) (0)
Estrogen receptor gets a grip on RNA (2021) (0)
Cyclic AMP Modulation of Estrogen-Induced Effects: A Novel Mechanism for Hormonal Resistance in Breast Cancer. (1997) (0)
Alternatives to phenol-based estrogen receptor ligands (2003) (0)
Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with an N-trifluoroethyl 4-chlorobenzyl OBHS-N derivative (2016) (0)
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance (2018) (0)
INVESTIGATION OF THE ROLE OF CUZD1-STAT5 SIGNALING IN MAMMARY GLAND DEVELOPMENT AND BREAST CANCER BY JANELLE MAPES DISSERTATION Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Molecular and Integrative Physiology (2017) (0)
Crystal Structure of the Estrogen Receptor Alpha Ligand Binding Domain Mutant 537S Complexed with Genistein (2008) (0)
Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with an N-methyl Substituted OBHS-N derivative (2016) (0)
Erratum: Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis (Science Translational Medicine (2015) 7 (274er1)) (2015) (0)
Gene and Proliferation Programs Signal-Regulated Kinase 2 in Regulating and Extracellular α Receptor Collaboration of Estrogen (2013) (0)
Science Signaling podcast for 24 May 2016: Designer estrogens (2016) (0)
Abstract P5-04-06: Withdrawn (2019) (0)
Abstract 946: Suppression of breast cancer metastasis and extension of host animal survival by a new adamantyl antiestrogen, K-07, in a preclinical breast cancer metastasis model driven by constitutively active mutant estrogen receptors (2018) (0)
Abstract C85: FOXM1-dependent gene expression program controls cancer stem cell and metastasis properties of breast cancer cells (2013) (0)
Crystal Structure of the Estrogen Receptor Alpha Ligand Binding Domain Complexed with an Oxabicyclic diarylethylene Compound (2008) (0)
Selective activators of estrogen receptor beta based on the aldoxime and ketoxime scaffolds (2012) (0)
in the Short-Term and Long-Term Absence of Estrogens Receptor Content of MCF-7 Human Breast Cancer Cells Grown Proliferation , Hormonal Responsiveness , and Estrogen Updated (2006) (0)
Effective combination treatments for breast cancer inhibition by FOXM1 inhibitors with other targeted cancer drugs (2023) (0)
Evaluation of wild yam (Dioscorea villosa) root extract as a potential epigenetic agent in breast cancer cells (2014) (0)
AntiestrogenModulationof the Growthand Propertiesof Ovarian Autonomousand Ovarian-DependentMammaryTumors in Rat & (2006) (0)
Genome-Wide Dynamics of Chromatin Binding of Estrogen Receptors (cid:1) and (cid:2) : Mutual Restriction and Competitive Site Selection (2009) (0)
Abstract 4053: A label-free spectroscopic signature associated with hormone sensitivity in 3D co-culture models of breast cancer (2012) (0)
ESTROGEN AND ANTIESTROGEN REGULATION OF PROLIFERATION AND PROTEIN SYNTHESIS OF HUMAN BREAST CANCER CELLS (1988) (0)
Crystal Structure of the Estrogen Receptor Alpha Ligand Binding Domain Complexed with a Chloro-Indazole Compound (2008) (0)
Abstract 1074: Genome-wide analysis of FOXM1 binding and involvement of FOXM1 in cancer stem cell and metastasis properties of endocrine-sensitive and resistant breast cancer cells. (2013) (0)
Non-estrogenic Xanthohumol Derivatives Mitigate Insulin Resistance and Cognitive Impairment in High-Fat Diet-induced Obese Mice (2018) (0)
Abstract P6-04-10: Combining direct and indirect modes of antiestrogen ligand antagonism of estrogen receptor activity in breast cancer (2020) (0)
Responsiveness during the Progression of MCF-7 Human Breast Cancer Cells to Estrogen-Autonomous Growth1 (1994) (0)
Acetylation regulates estrogen receptoralpha transactivation (2000) (0)
Aminobenzothiazoles as beta-Selective Estrogen Receptor Ligands (2006) (0)

This paper list is powered by the following services:

Other Resources About Benita Katzenellenbogen

en.wikipedia.org

What Schools Are Affiliated With Benita Katzenellenbogen?

Benita Katzenellenbogen is affiliated with the following schools:

Benita Katzenellenbogen's Academic­Influence.com Rankings

Why Is Benita Katzenellenbogen Influential?

Benita Katzenellenbogen's Published Works

Published Works

Other Resources About Benita Katzenellenbogen

What Schools Are Affiliated With Benita Katzenellenbogen?

Benita Katzenellenbogen's AcademicInfluence.com Rankings